June 2025 · Video
Conversation with Ignacio Nunez about C> landscape in 2025
A conversation about market dynamics, manufacturing challenges, and bringing advanced therapies to patients at scale.
Watch on YouTube ↗Accelerating Life‑Saving Therapies
We help biotech companies deploy LEAN enterprise methodologies to speed up cell therapy operations, bringing breakthrough treatments to patients faster.
Our Expertise
Specialized LEAN consulting designed specifically for the unique challenges of cell therapy development and manufacturing.
Process Optimization
Streamline your cell therapy development pipeline with proven LEAN methodologies, reducing time-to-market by up to 60% .
Quality Excellence
Implement robust quality systems that meet regulatory standards while maintaining operational efficiency and scalability.
Team Transformation
Build high-performing teams through LEAN training and culture transformation, ensuring sustainable operational improvements.
Proven Results for Biotech Leaders
Our LEAN enterprise approach has helped cell therapy companies optimize their operations, reduce waste, and accelerate patient access to breakthrough treatments.
Accelerate therapy development timelines
Reduce operational costs by 25–60%
Improve regulatory compliance readiness
Scale manufacturing capabilities efficiently
Enhance cross-functional collaboration
60%
Faster Time‑to‑Market
20+
Companies Served
$100M+
Costs Saved
We save you time and money so you can focus on what really matters, saving lives..
Ready to Transform Your Operations?
Join the biotech teams who trust BioExcellence to optimize their cell therapy development and manufacturing processes.
Schedule Your Free ConsultationFounder & Principal
Ignacio Nunez is a seasoned operator and manufacturing executive with deep expertise in biologics, cell and gene therapies, and complex GMP manufacturing systems. He has spent his career helping organizations translate breakthrough therapies into scalable, reliable operations.
Most recently, Ignacio served as Chief Operating Officer of CellReady, where he led the company’s operational expansion in the cell and gene therapy space. He drove large-scale organizational and manufacturing transformations, delivering material reductions in capital expenditure and development timelines while strengthening GMP manufacturing, quality systems, and supply chain performance across collaborations with global biopharma, emerging biotech, academic institutions, investors, and CDMOs/CROs.
Earlier, Ignacio contributed hands-on to the industrialization and commercialization of next-generation therapies, including some of the first FDA-approved cell and gene therapies. He founded BioExcellence to bring operator-led execution to clients—developing high-throughput manufacturing and operational excellence models adopted in the design and optimization of large-scale cell therapy production facilities.
Ignacio holds B.S. and M.Sc. degrees in Chemical Engineering from the University of Granada and is a certified Lean Six Sigma Master Black Belt.
“Operational excellence is disciplined execution that saves time, capital, and ultimately helps patients receive life-saving therapies sooner.”
Case Studies
Case Study 1
Allogeneic T-Cell Therapy Company
Challenge
- Low manufacturing success rates and unpredictable throughput
- Excessive open handling steps driving contamination risk and batch loss
- High cost of goods driven by inefficient use of single-use expansion systems and QC fragmentation
Approach
- End-to-end capacity and process analysis across stimulation, expansion, harvest, and QC
- Identified root causes of low yield and variability (seeding density, media strategy, expansion surface area)
- Redesigned expansion strategy and batch architecture to reduce handling steps and improve consistency
- Modeled organizational and staffing requirements aligned to realistic throughput targets
Impact
- Clear path to ~70%+ manufacturing success rates
- Identified multi-million-dollar annual cost-reduction opportunities through yield improvement and process simplification
- Enabled 2–4× increase in effective output per batch without adding facilities
(Derived from operational debrief and capacity analysis; client name and product withheld for confidentiality.)
Case Study 2
Cell & Gene Therapy CDMO
Challenge
- New CGT facility design at risk of underutilization and future bottlenecks
- Capacity projections disconnected from real process constraints
- Need to balance flexibility with capital efficiency
Approach
- Led a structured capacity workshop using Lean / DMAIC principles
- Mapped end-to-end autologous and allogeneic workflows (TIL, TCR, CAR-T)
- Quantified throughput limits by equipment, staffing, and shift design
- Provided layout and equipment recommendations to maximize utilization
Impact
- Data-driven facility design inputs aligned to maximum achievable throughput
- Improved asset utilization assumptions without increasing square footage
- Reduced risk of premature capital expansion while preserving scalability
(Representative CDMO engagement; specific organization anonymized.)
Case Study 3
G-Rex-Centric CDMO Platform
Challenge
- Rapid scale-up required without runaway capital spend
- Fragmented operational ownership and limited cost visibility
- Facility, staffing, and quality systems misaligned with actual demand
Approach
- Operator-led stabilization of manufacturing, quality, facilities, and supply chain
- Implemented disciplined cost controls, inventory management, and PO governance
- Optimized facility layout, utilities, and monitoring systems for reliability and scale
- Built training, staffing, and leadership models aligned to high-throughput G-Rex manufacturing
Impact
- $1.6M+ structural annual cost reduction while expanding operational capability
- Stabilized GMP operations through facility expansion and systems integration
- Enabled rapid, capital-efficient scale-up for multiple cell therapy clients
(Engagement details anonymized; outcomes representative of G-Rex-centric CDMO transformations.)
Insights
Conversations on cell and gene therapy manufacturing, partnerships, and expanding patient access.
Videos
March 2025 · Video
ATW 2025: Key Partnerships in CGT
Ignacio discusses collaboration between ScaleReady and Cellular Origins and its impact on drug development and patient access.
Watch on YouTube ↗
September 2024 · Video
ATE 2024: Interview with Ignacio Núñez
Perspectives on the evolving cell and gene therapy manufacturing landscape and scaling access globally.
Watch on YouTube ↗Articles
July 14, 2026 · Article
Controlling the Cost of Cell Therapy Manufacturing: Why a Sub-$100K Cell Therapy Is Possible
How process simplification, closed workflows, integrated quality control, and a focus on access can reshape manufacturing costs.
Read article ↗July 8, 2026 · Article
The Hidden Cost of Open Processing in Cell Therapy
Why open processing adds cost, consumes capacity, and limits throughput in cell therapy manufacturing.
Read article ↗July 1, 2026 · Article
When Consultants Make Sense: Converting Fixed Cost into Operational Capability
How targeted consulting can accelerate manufacturing readiness and transformation while managing fixed costs.
Read article ↗January 23, 2026 · Article
Simplicity Wins: How Lean Principles and Smart Automation Can Reshape Pharma Manufacturing
How Lean thinking and smart automation can improve pharmaceutical manufacturing.
Read article ↗November 1, 2024 · Article
Get Into My CAR-T
A look at the manufacturing and logistics behind delivering CAR-T therapy to patients.
Read article ↗April 9, 2021 · Article
Entrevista con Alejandro Madrigal: científico mexicano y referente mundial
An interview with Alejandro Madrigal on his scientific career and commitment to social change.
Read article ↗Let’s Discuss Your Project
Connect with our LEAN experts to explore how we can accelerate your cell therapy operations.